Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Medico Remedies Limited is an Indian specialty and generic pharmaceutical manufacturer operating in domestic and export markets. The company demonstrates strong profitability metrics with 24.1% operating margins and 18.8% ROE, suggesting efficient operations and pricing power in its therapeutic segments. Recent performance shows margin expansion (net income growth of 21.7% vs revenue growth of 4.2%), indicating operational leverage and product mix improvements despite modest top-line growth.
Medico generates revenue through manufacturing and selling generic pharmaceutical formulations with 28.2% gross margins, benefiting from India's cost-competitive manufacturing base and established API (Active Pharmaceutical Ingredient) sourcing networks. The company's 24.1% operating margin suggests strong operational efficiency and scale advantages in production. Pricing power derives from regulatory approvals, bioequivalence certifications, and distribution relationships in both domestic and export markets. The low debt-to-equity ratio of 0.19 indicates conservative financial management and ability to self-fund growth initiatives. Revenue growth of 4.2% coupled with 21.7% net income growth demonstrates operating leverage as fixed manufacturing costs are spread over larger volumes and product mix shifts toward higher-margin specialty formulations.
New product approvals and launches in domestic market, particularly in chronic therapy segments with recurring revenue potential
US FDA and European regulatory approvals for export formulations, which command premium pricing and expand addressable markets
API and raw material cost fluctuations, especially for imported ingredients priced in USD, affecting gross margins
Rupee-dollar exchange rate movements impacting export realization and import costs for raw materials
Competitive intensity in key generic molecules as patents expire and biosimilar competition intensifies
Increasing regulatory scrutiny from US FDA and European regulators on Indian manufacturing facilities, with potential for warning letters or import bans that could disrupt export revenue streams
Price erosion in generic pharmaceutical markets as competition intensifies post-patent expiry, particularly in high-volume molecules where multiple manufacturers enter simultaneously
Government price controls in India through National Pharmaceutical Pricing Authority (NPPA) affecting domestic margins on essential medicines
Shift toward biosimilars and complex generics requiring higher R&D investment and manufacturing capabilities that may favor larger competitors
Intense competition from larger Indian pharmaceutical manufacturers (Sun Pharma, Dr. Reddy's, Cipla) with greater scale, R&D budgets, and global distribution networks
Chinese API manufacturers offering lower-cost raw materials, creating margin pressure for Indian formulation companies dependent on imported ingredients
Consolidation among pharmaceutical distributors and hospital purchasing groups increasing buyer power and pressuring realized prices
Zero reported operating cash flow and free cash flow in recent period raises concerns about working capital management, cash conversion efficiency, or potential accounting timing issues requiring investigation
Current ratio of 1.62 is adequate but not exceptional for pharmaceutical sector, suggesting limited buffer for unexpected working capital needs or inventory write-downs
High valuation multiples (21.7x EV/EBITDA, 5.9x P/B) create downside risk if growth expectations are not met or if sector multiples compress
low - Pharmaceutical demand is relatively inelastic as medications address essential health needs regardless of economic conditions. However, discretionary healthcare spending and elective procedures show modest cyclicality. Generic drug consumption in India benefits from government healthcare initiatives and insurance penetration, providing stability. Export demand to developed markets remains steady due to chronic disease prevalence and aging demographics.
Moderate sensitivity through multiple channels: (1) With 0.19 debt-to-equity ratio, direct financing cost impact is minimal, but rising rates in India affect working capital financing costs for inventory and receivables; (2) Rupee depreciation typically accompanies rate differentials between India and developed markets, benefiting export realizations but increasing costs for imported APIs; (3) Valuation multiples compress as discount rates rise, particularly impacting the 21.7x EV/EBITDA multiple which is elevated for a mature pharmaceutical manufacturer.
Minimal direct credit exposure given the healthcare sector's essential nature and government/insurance reimbursement mechanisms. However, working capital dynamics are important: pharmaceutical distributors and hospital systems in India can have extended payment cycles (60-90 days typical), making the 1.62 current ratio relevant for liquidity management. Export receivables from international markets generally have better payment terms but carry currency risk.
value - The stock trades at 2.1x price-to-sales with strong profitability metrics (24.1% operating margin, 18.8% ROE) but has declined 29% over one year, suggesting value investors are attracted to the disconnect between operational performance and market valuation. The 21.7% net income growth despite modest 4.2% revenue growth appeals to investors seeking margin expansion stories. However, zero reported cash flow raises concerns that may deter quality-focused value investors until resolved.
moderate-to-high - The -29% one-year return combined with +12.9% six-month return and -9.6% three-month return demonstrates significant volatility typical of mid-cap Indian pharmaceutical stocks. Volatility drivers include regulatory news (FDA inspections), currency fluctuations (rupee movements), and sector rotation in emerging markets. The 22% EPS growth volatility relative to 4.2% revenue growth indicates earnings sensitivity to operational and margin factors.
